Drug Profile
MSM 608
Alternative Names: MSM-608Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator MSM Protein Technologies
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glioma
Most Recent Events
- 06 Sep 2023 MSM 608 is still in preclinical trials for Glioma in USA (MSM Protein Technologies pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Glioma in USA
- 15 Jul 2016 MSM 608 is available for licensing- http://msmprotein.com/about/